BSX - Boston Scientific Corporation
| Previous close | 42.61 |
| Open | 42.49 |
| Bid | 42.25 x 1000 |
| Ask | 42.26 x 1400 |
| Day's range | 41.87 - 42.52 |
| 52-week range | 31.56 - 43.84 |
| Volume | 1,400,031 |
| Avg. volume | 6,955,396 |
| Market cap | 58.896B |
| Beta (3Y monthly) | 0.77 |
| PE ratio (TTM) | 54.88 |
| EPS (TTM) | 0.77 |
| Earnings date | 4 Feb 2020 - 10 Feb 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.36 |
- Zacks
Safety Notice Issued by Boston Scientific (BSX) for AngioJet
Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.
- Simply Wall St.
How Good Is Boston Scientific Corporation (NYSE:BSX), When It Comes To ROE?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Yahoo Finance
Which Companies Recently Raised Guidance?
Third-quarter EPS season is in the homestretch, with blue-chip Utilities, Financial Services, Consumer and Industrial companies all releasing reports. Through 11/1/2019, Refinitiv reported that 356 S&P 500 companies have now announced 3Q earnings, with 76% coming in above consensus, ahead of the past four-quarters average percentage of 74%. The better-than-expected results have improved the overall forecast for the quarter to a -0.8%, from -3.2% at the start of the reporting season. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management’s ability to “raise guidance” can often be a catalyst to strong returns in the quarters ahead. Following are 12 BUY-rated companies in Argus coverage for which management has raised guidance during the current EPS reporting season.
- Bloomberg
Index Bets on a Path to Higher Returns With Gay-Friendly Firms
(Bloomberg) -- A California firm is betting that public companies supported by gay people will outperform the market.LGBTQ Loyalty Holdings Inc. on Wednesday is launching an index comprised of 100 companies that support equality for lesbian, gay, bisexual, transgender and queer people -- and which has better returns than the S&P 500. Companies listed in the new index come, in part, from the results of a poll asking people in the U.S. who identify as LGBTQ which companies they want included.While there are other stock indexes of companies focused on rights for gay people, the LGBTQ100 ESG Index is the first environmental, social and governance benchmark to seek constituent input for its makeup, according to West Hollywood-based LGBTQ Loyalty Holdings. The company worked with Harris Insights & Analytics LLC to conduct the poll. All companies in the index are S&P 500 firms with top scores from the Human Rights Campaign.That means the index isn’t made up simply of companies with nondiscrimination policies and equitable benefits, but are also firms “LGBT people find attractive and interesting,” former U.S. Representative Barney Frank, an LGBTQ Loyalty Holdings board member, said in a telephone interview.A focus on LGBTQ rights has become more widespread among large U.S. companies. This year, 571 firms received perfect scores from the Human Rights Campaign, up from just 13 in 2003, when the rankings were introduced. For the index, aside from the survey, a combination of quantitative methods and ESG ratings from Institutional Shareholder Services Inc. are used to select the 100 companies from the 193 S&P 500 companies with unblemished scores for benefits, culture and anti-discrimination policies.LGBTQ Loyalty Holdings -- led by Chief Executive Officer Bobby Blair, and whose board members include Billy Bean, Major League Baseball’s ambassador for inclusion -- is now working to set up an exchange-traded fund linked to the index. The ETF, which is under review by the Securities and Exchange Commission, will cost 75 basis points, or $75 per $10,000 invested, according to the company. While the median U.S. ETF charges 48 basis points, socially focused funds tend to be more expensive.UBS Group AG helped start a similar ETF focused on gay rights last year that charges 65 basis points, and the Alps Workplace Equality Portfolio Fund charged 75 basis points. Such investment vehicles are not always successful: The Alps fund closed on April 26 “on consideration of the fund’s inability to attract significant market interest.”Over the past five years, the LGBTQ100 has had annualized returns of almost 12%, compared with 7.8% for the S&P 500, according to the company. Cisco Systems Inc., Amazon.com Inc., Boston Scientific Corp., Apple Inc. and Coca-Cola Co. are among the most heavily weighted companies in the index.By buying those stocks, investors “can serve their principles without a financial sacrifice,” Frank said.(Updates with details of index companies in penultimate paragraph. A previous version of this story corrected Billy Bean reference in sixth paragraph.)To contact the reporter on this story: Gwen Everett in New York at geverett10@bloomberg.netTo contact the editors responsible for this story: Michael J. Moore at mmoore55@bloomberg.net, Daniel TaubFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks
Boston Scientific (BSX) Catches Eye: Stock Jumps 5%
Boston Scientific (BSX) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.
- Zacks
Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View
Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.
- Zacks
Boston Scientific (BSX) Q3 Earnings and Revenues Beat Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
- Zacks
Medical Products Industry Outlook: Prospects Seem Promising
Medical Products Industry Outlook: Prospects Seem Promising
- Zacks
Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
- Simply Wall St.
Is Boston Scientific's (NYSE:BSX) Share Price Gain Of 200% Well Earned?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Zacks
Boston Scientific (BSX) Earnings Expected to Grow: Should You Buy?
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
- Zacks
Abiomed's (ABMD) Impella 5.5 With SmartAssist Gets FDA Nod
Abiomed's (ABMD) flagship Impella heart pump line is a major growth driver.
- Zacks
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
- Zacks
PETQ vs. BSX: Which Stock Is the Better Value Option?
PETQ vs. BSX: Which Stock Is the Better Value Option?
- Zacks
Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
- Simply Wall St.
Boston Scientific Corporation (NYSE:BSX) Insiders Have Been Selling
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Zacks
BAX or BSX: Which Is the Better Value Stock Right Now?
BAX vs. BSX: Which Stock Is the Better Value Option?
- Zacks
IoMT Becomes the Buzzword in New Age MedTech Investing
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
- Simply Wall St.
Does Boston Scientific Corporation's (NYSE:BSX) CEO Pay Reflect Performance?
Mike Mahoney has been the CEO of Boston Scientific Corporation (NYSE:BSX) since 2012. First, this article will compare...
- Zacks
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
- Zacks
Boston Scientific (BSX) Up 1.6% Since Last Earnings Report: Can It Continue?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
BAX vs. BSX: Which Stock Is the Better Value Option?
BAX vs. BSX: Which Stock Is the Better Value Option?
